The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
Open accessAbstract
Newcastle disease virus (NDV) is an avian paramyxovirus, which has been demonstrated to possess significant oncolytic activity against mammalian cancers. This review summarizes the research leading to the elucidation of the mechanisms of NDV-mediated oncolysis, as well as the development of novel oncolytic agents through the use of genetic engineering. Clinical trials utilizing NDV strains and NDV-based autologous tumor cell vaccines will expand our knowledge of these novel anticancer strategies and will ultimately result in the successful use of the virus in the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Khattar, S. K., Samal, S., DeVico, A. L., Collins, P. L., & Samal, S. K. (2011) · Journal of Virology · doi:10.1128/jvi.05050-11 · Cited by 37
RetractedImproved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
History of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763
Nagai, Y., Klenk, H.-D., & Rott, R. (1976) · Virology · doi:10.1016/0042-6822(76)90178-1 · Cited by 646
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Multiple Anti-Interferon Actions of the Influenza A Virus NS1 Protein
Kochs, G., García-Sastre, A., & Martínez-Sobrido, L. (2007) · Journal of Virology · doi:10.1128/jvi.02581-06 · Cited by 445
Recognition of viruses by cytoplasmic sensors
Wilkins, C., & Gale, M. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.12.003 · Cited by 430
Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.016 · Cited by 407
Subversion of the actin cytoskeleton during viral infection
Taylor, M. P., Koyuncu, O. O., & Enquist, L. W. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2574 · Cited by 395
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Role of fusion protein cleavage site in the virulence of Newcastle disease virus
Panda, A., Huang, Z., Elankumaran, S., Rockemann, D. D., & Samal, S. K. (2004) · Microbial Pathogenesis · doi:10.1016/j.micpath.2003.07.003 · Cited by 320
Viral tricks to grid-lock the type I interferon system
Versteeg, G. A., & García-Sastre, A. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.05.009 · Cited by 256
Recombinant Newcastle Disease Virus as a Vaccine Vector
Nakaya, T., Cros, J., Park, M.-S., Nakaya, Y., Zheng, H., Sagrera, A., Villar, E., Garcı́a-Sastre, A., & Palese, P. (2001) · Journal of Virology · doi:10.1128/jvi.75.23.11868-11873.2001 · Cited by 250
Self-citationCytoplasmic DNA innate immune pathways
Barber, G. N. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01051.x · Cited by 245
Virulence of newcastle disease virus: what is known so far?
Dortmans, J. C., Koch, G., Rottier, P. J., & Peeters, B. P. (2011) · Veterinary Research · doi:10.1186/1297-9716-42-122 · Cited by 245
Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction
Park, M.-S., García-Sastre, A., Cros, J. F., Basler, C. F., & Palese, P. (2003) · Journal of Virology · doi:10.1128/jvi.77.17.9522-9532.2003 · Cited by 243
Self-citationThe Hemagglutinin-Neuraminidase Protein of Newcastle Disease Virus Determines Tropism and Virulence
Huang, Z., Panda, A., Elankumaran, S., Govindarajan, D., Rockemann, D. D., & Samal, S. K. (2004) · Journal of Virology · doi:10.1128/jvi.78.8.4176-4184.2004 · Cited by 237
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Melcher, A., Parato, K., Rooney, C. M., & Bell, J. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.65 · Cited by 232
Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease
Park, M., Steel, J., García‐Sastre, A., Swayne, D. E., & Palese, P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602566103 · Cited by 227
Self-citationToyoda, T., Sakaguchi, T., Imai, K., Inocencio, N. M., Gotoh, B., Hamaguchi, M., & Nagai, Y. (1987) · Virology · doi:10.1016/0042-6822(87)90261-3 · Cited by 227
Steiner, H. H., Bonsanto, M. M., Beckhove, P., Brysch, M., Geletneky, K., Ahmadi, R., Schuele-Freyer, R., Kremer, P., Ranaie, G., Matejic, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.038 · Cited by 216
Mader, E. K., Maeyama, Y., Lin, Y., Butler, G. W., Russell, H. M., Galanis, E., Russell, S. J., Dietz, A. B., & Peng, K.-W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1292 · Cited by 204
MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas
Csatary, L. K., Gosztonyi, G., Szeberenyi, J., Fabian, Z., Liszka, V., Bodey, B., & Csatary, C. M. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021735.85511.05 · Cited by 200
Sensing and Signaling in Antiviral Innate Immunity
O'Neill, L. A. J., & Bowie, A. G. (2010) · Current Biology · doi:10.1016/j.cub.2010.01.044 · Cited by 186
Stem Cell Collection and Gene Transfer in Fanconi Anemia
Kelly, P. F., Radtke, S., Kalle, C. V., Balcik, B., Bohn, K., Mueller, R., Schuesler, T., Haren, M., Reeves, L., Cancelas, J. A., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300033 · Cited by 180
Mansour, M., Palese, P., & Zamarin, D. (2011) · Journal of Virology · doi:10.1128/jvi.01537-10 · Cited by 168
Self-citationKrishnamurthy, S., Takimoto, T., Scroggs, R. A., & Portner, A. (2006) · Journal of Virology · doi:10.1128/jvi.02618-05 · Cited by 158
Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements
Khabar, K. S. A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0383-x · Cited by 157
Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.
Lorence, R. M., Katubig, B. B., Reichard, K. W., Reyes, H. M., Phuangsab, A., Sassetti, M., Walter, R. J., & Peeples, M. E. (1994) · PubMed · Cited by 156
Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis
Dorer, D. E., & Nettelbeck, D. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.013 · Cited by 154
Fiola, C., Peeters, B. P. H., Fournier, P., Arnold, A., Bucur, M., & Schirrmacher, V. (2006) · International Journal of Cancer · doi:10.1002/ijc.21821 · Cited by 147
Lorence, R. M., Rood, P. A., & Kelley, K. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.16.1305 · Cited by 145
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 145
Schulze, T., Kemmner, W., Weitz, J., Wernecke, K. ‐., Schirrmacher, V., & Schlag, P. M. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0526-1 · Cited by 139
Schirrmacher, V., & Fournier, P. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-561-9_30 · Cited by 136
Ockert, D., Schirrmacher, V., Beck, N., et al. (1996) · PubMed · Cited by 131
Schirrmacher, V. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0602-0 · Cited by 124
Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector
Martínez‐Sobrido, L., Gitiban, N., Fernández-Sesma, A., Cros, J. F., Mertz, S. E., Jewell, N. A., Hammond, S., Flaño, E., Durbin, R. K., García‐Sastre, A., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.3.1130-1139.2006 · Cited by 123
Zeng, J., Fournier, P., & Schirrmacher, V. (2002) · Virology · doi:10.1006/viro.2002.1413 · Cited by 121
Attenuated veterinary virus vaccine for the treatment of cancer.
Csatáry, L. K., Eckhardt, S., Bukosza, I., et al. (1993) · PubMed · Cited by 114
Batliwalla, F., Bateman, B. A., Serrano, D., et al. (1998) · Molecular Medicine · doi:10.1007/bf03401771 · Cited by 114
Ge, J., Wang, X., Tao, L., Wen, Z., Feng, N., Yang, S., Xia, X., Yang, C., Chen, H., & Bu, Z. (2011) · Journal of Virology · doi:10.1128/jvi.00519-11 · Cited by 114
Schlag, P., Manasterski, M., Gerneth, T., et al. (1992) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741145 · Cited by 112
Ogasawara, T., Gotoh, B., Suzuki, H., Asaka, J., Shimokata, K., ROTT, R., & Nagai, Y. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05076.x · Cited by 111
Washburn, B., Weigand, M. A., Große-Wilde, A., Janke, M., Stahl, H. F., Rieser, E., Sprick, M. R., Schirrmacher, V., & Walczak, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1814 · Cited by 108
Ahlert, T., Sauerbrei, W., Bastert, G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1354 · Cited by 106
Zamarin, D., Martínez‐Sobrido, L., Kelly, K. J., Mansour, M., Sheng, G., Vigil, A., García‐Sastre, A., Palese, P., & Fong, Y. (2009) · Molecular Therapy · doi:10.1038/mt.2008.286 · Cited by 102
Self-citationUse of Newcastle Disease Virus Vaccine (MTH-68/H) in a Patient With High-grade Glioblastoma
Csatáry, L. K., & Bakács, T. (1999) · JAMA · doi:10.1001/jama.281.17.1588-a · Cited by 97
Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
Elankumaran, S., Chavan, V., Qiao, D., Raghunath, S., Moorkanat, G., Biswas, M., & Samal, S. K. (2010) · Journal of Virology · doi:10.1128/jvi.01553-09 · Cited by 95
Karcher, J., Dyckhoff, G., Beckhove, P., Reisser, C., Brysch, M., Ziouta, Y., Helmke, B. H., Weidauer, H., Schirrmacher, V., & Herold‐Mende, C. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1545 · Cited by 94
Liang, W., Wang, H., Sun, T.-M., Yao, W.-Q., Chen, L.-L., Jin, Y., Li, C., & Meng, F. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i3.495 · Cited by 92
Springfeld, C., von Messling, V., Frenzke, M. E., Ungerechts, G., Buchholz, C. J., & Cattaneo, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0538 · Cited by 90
Csatáry, L. K., Moss, R. W., Beuth, J., Törőcsik, B., Szeberényi, J., & Bakács, T. (1999) · PubMed · Cited by 87
Fábián, Z., Csatary, C. M., Szeberényi, J., & Csatáry, L. K. (2007) · Journal of Virology · doi:10.1128/jvi.02490-06 · Cited by 87
Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy
Vigil, A., Martinez, O., Chua, M. A., & García‐Sastre, A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.181 · Cited by 87
DiNapoli, J. M., Yang, L., Samal, S. K., Murphy, B. R., Collins, P. L., & Bukreyev, A. A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.024 · Cited by 86
Ilan, Y., Sauter, B. V., Chowdhury, N. R., Reddy, B., Thummala, N. R., Droguett, G., Davidson, A., Ott, M., Horwitz, M. S., & Chowdhury, J. R. (1998) · Hepatology · doi:10.1002/hep.510270525 · Cited by 84
Kim, S., Subbiah, M., Samuel, A. S., Collins, P. L., & Samal, S. K. (2011) · Journal of Virology · doi:10.1128/jvi.00652-11 · Cited by 83
Garten, W., Berk, W., Nagai, Y., ROTT, R., & Klenk, H. (1980) · Journal of General Virology · doi:10.1099/0022-1317-50-1-135 · Cited by 82
Genetically engineered Newcastle disease virus for malignant melanoma therapy
Zamarin, D., Vigil, A., Kelly, K. J., García‐Sastre, A., & Fong, Y. (2009) · Gene Therapy · doi:10.1038/gt.2009.14 · Cited by 81
Self-citationSchirrmacher, V. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000223 · Cited by 80
Directing systemic oncolytic viral delivery to tumors via carrier cells☆
Nakashima, H., Kaur, B., & Chiocca, E. A. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.02.004 · Cited by 70
Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
Yaacov, B., Elihaoo, E., lazar, I., Ben-Shlomo, M., Greenbaum, I., Panet, A., & Zakay-Rones, Z. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.31 · Cited by 69
Puhlmann, J., Puehler, F., Mumberg, D., Boukamp, P., & Beier, R. (2010) · Oncogene · doi:10.1038/onc.2009.507 · Cited by 66
Termeer, C., Schirrmacher, V., Bröcker, E., & Becker, J. C. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700109 · Cited by 66
Peng, K.-W., Vile, R. G., Cosset, F., & Russell, S. J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300982 · Cited by 66
Lazar, I., Barak, Y., Shiloach, T., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00401-09 · Cited by 62
Use of attenuated paramyxoviruses for cancer therapy
Lech, P. J., & Russell, S. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.124 · Cited by 58
Richards, K. H., & Macdonald, A. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2010.12.007 · Cited by 55
Umansky, V., Shatrov, V. A., Lehmann, V., & Schirrmacher, V. (1996) · International Immunology · doi:10.1093/intimm/8.4.491 · Cited by 55
Kinoh, H., Inoue, M., Washizawa, K., Yamamoto, T., Fujikawa, S., Tokusumi, Y., Iida, A., Nagai, Y., & Hasegawa, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302272 · Cited by 48
Ahmed, A. U., Thompson, J., Emiliusen, L., Murphy, S. J., Beauchamp, R. D., Suzuki, K., Alemany, R., Harrington, K. J., & Vile, R. G. (2003) · Nature Biotechnology · doi:10.1038/nbt835 · Cited by 46
Maamary, J., Array, F., Gao, Q., García-Sastre, A., Steinman, R., Palese, P., & Nchinda, G. (2010) · Journal of Virology · doi:10.1128/jvi.02036-10 · Cited by 45
Self-citationSilberhumer, G. R., Brader, P., Wong, J., Serganova, I. S., Gönen, M., González, S. J., Blasberg, R. G., Zamarin, D., & Fong, Y. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0090 · Cited by 43
Self-citationPlaksin, D., Porgador, A., Vadai, E., Feldman, M., Schirrmacher, V., & Eisenbach, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590615 · Cited by 42
Schirrmacher, V. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1222 · Cited by 42
Fábián, Z., Törőcsik, B., Kiss, K., et al. (2001) · PubMed · Cited by 41
Molouki, A., Hsu, Y., Jahanshiri, F., et al. (2009) · Intervirology · doi:10.1159/000264198 · Cited by 40
A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen
Xiao, S., Kumar, M., Yang, X., Akkoyunlu, M., Collins, P. L., Samal, S. K., & Pal, U. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.010 · Cited by 33
Haas, C., Lulei, M., Fournier, P., Arnold, A., & Schirrmacher, V. (2005) · International Journal of Cancer · doi:10.1002/ijc.21390 · Cited by 31
Haas, C., Lulei, M., Fournier, P., Arnold, A., & Schirrmacher, V. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.10.031 · Cited by 28
Ni, J., Galani, I. E., Cerwenka, A., Schirrmacher, V., & Fournier, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.12.005 · Cited by 26
Voit, C. A., Kron, M., Schwürzer‐Voit, M., & Sterry, W. (2003) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1046/j.1610-0387.2003.02014.x · Cited by 25
CLINICAL STUDIES EMPLOYING INTERFERON INDUCERS IN MAN AND ANIMALS *
Merigan, T. C., Clercq, E. D., Finkelatein, M. S., Clever, L. H., Walker, S. M., & Waddell, D. (1970) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1970.tb53468.x · Cited by 23
Kim, D., Martínez‐Sobrido, L., Choi, C., Petroff, N., García‐Sastre, A., Niewiesk, S., & Carsillo, T. (2010) · Journal of Virology · doi:10.1128/jvi.01624-10 · Cited by 21
Schirrmacher, V. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1033 · Cited by 19
Bian, H., Fournier, P., Moormann, R. J. M., Peeters, B. P. H., & Schirrmacher, V. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.2.431 · Cited by 19
Reactions of Human Sera to Avian Adenoviruses and Newcastle Disease Virus
Miller, L. T., & Yates, V. J. (1971) · Avian Diseases · doi:10.2307/1588867 · Cited by 17
Further Observations on the Inhibitory Effect of Myxoviruses on a Transplantable Murine Leukemia
Eaton, M. D., & Scala, A. R. (1969) · Experimental Biology and Medicine · doi:10.3181/00379727-132-34138 · Cited by 12
Acute T-cell leukemia/lymphoma mimicking Hodgkin's disease with secondary HTLV I seroconversion
Picard, F., Dreyfus, F., Guern, M. L., Tulliez, M., d’Auriol, L., Neron, S., Galibert, F., Saragosti, S., & Varet, B. R. (1990) · Cancer · doi:10.1002/1097-0142(19901001)66:7<1517::aid-cncr2820660714>3.0.co;2-i · Cited by 12
Schirrmacher, V. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000796 · Cited by 9
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Self-citationIntegrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Metadata
- Authors
- Zamarin, D., & Palese, P.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2012-03
- Volume
- 7
- Issue
- 3
- Pages
- 347-367
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2123291849
- Cited by
- 254
- References
- 95
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.